Updating results

158 results for kidney cancer

Sort: Relevance | Date

Renal cancer

Everything NICE has said on renal (kidney) cancer in an interactive flowchart

NICE Pathway Published December 2013 Last updated May 2019

Percutaneous cryotherapy for renal cancer (IPG402)

Evidence-based recommendations on percutaneous cryotherapy for renal (kidney) cancer

Interventional procedures guidance Published July 2011

Laparoscopic nephrectomy (including nephroureterectomy) (IPG136)

Evidence-based recommendations on laparoscopic nephrectomy (including nephroureterectomy; keyhole surgery to remove a kidney)

Interventional procedures guidance Published August 2005

Irreversible electroporation for treating renal cancer (IPG443)

Evidence-based recommendations on irreversible electroporation (IRE) for treating renal (kidney) cancer

Interventional procedures guidance Published February 2013

Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)

Evidence-based recommendations on sunitinib (Sutent) for the first-line treatment of advanced and/or metastatic renal cell carcinoma

Technology appraisal guidance Published March 2009

Percutaneous radiofrequency ablation for renal cancer (IPG353)

Evidence-based recommendations on percutaneous radiofrequency ablation for treating renal (kidney) cancer

Interventional procedures guidance Published July 2010

Laparoscopic cryotherapy for renal cancer (IPG405)

Evidence-based recommendations on laparoscopic cryotherapy (keyhole surgery to destroy cancer cells by freezing) for treating renal (kidney) cancer

Interventional procedures guidance Published August 2011

Avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547]

In development [GID-TA10459] Expected publication date: 08 April 2020

Technology appraisal guidance In development

Pembrolizumab with axitinib for untreated metastatic renal cell carcinoma ID1426

In development [GID-TA10331] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)

Technology appraisal guidance Published February 2011 Last updated August 2013

Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

Evidence-based recommendations on axitinib (Inlyta) for treating advanced renal cell carcinoma (RCC) (kidney cancer) when prior systemic treatment has failed

Technology appraisal guidance Published February 2015

Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

Evidence-based recommendations on evacizumab (Avastin), soradenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for renal cell carcinoma

Technology appraisal guidance Published August 2009

Acute kidney injury: prevention, detection and management (CG169)

This guideline covers preventing, detecting, and managing acute kidney injury in children (aged above 1 month and below 12 years), young people (aged 12 to 17 years) and adults (aged 18 years or older). It aims to improve assessment and detection by non-specialist clinicians, and specifies when they should refer people to specialist services. This will reduce the chance of death or complications for people at risk of acute kidney injury.

Clinical guideline Published August 2013

Acute kidney injury (QS76)

This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. Acute kidney injury is sudden damage to the kidneys, which can sometimes result in kidney failure. The quality standard includes assessment by non-specialists and when to refer to specialist services. It describes high-quality care in priority areas for improvement.

Quality standard Published December 2014

Kidney conditions

Everything NICE has said on kidney (renal) conditions in an interactive flowchart

NICE Pathway Published May 2015 Last updated May 2018

Urinary incontinence in neurological disease: assessment and management (CG148)

This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

Clinical guideline Published August 2012

Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma (kidney cancer) after previous treatment

Technology appraisal guidance Published February 2017

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (CG144)

This guideline covers the diagnosis and management of venous thromboembolic diseases in adults (aged 18 and over), and the role of thrombophilia testing. It aims to clarify which diagnostic tests should be used, reduce variation in pharmacological therapies, and provide guidance on when thrombophilia testing is useful.

Clinical guideline Published June 2012 Last updated November 2015

Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma (kidney cancer) in adults

Technology appraisal guidance Published August 2017

Renal replacement therapy services for adults (QS72)

This quality standard covers renal replacement therapy services for adults with kidney failure. It includes treatment options, such as dialysis and kidney transplant. It describes high-quality care in priority areas for improvement.

Quality standard Published November 2014 Last updated October 2018

Chronic kidney disease: managing anaemia (NG8)

This guideline covers diagnosing, assessing, managing and monitoring anaemia in people with chronic kidney disease. It aims to improve care for people with chronic kidney disease by specifying how to assess when their anaemia needs treating, and by making detailed recommendations on treatment with erythropoietic stimulating agents (ESAs) and iron. It also covers detecting and managing ESA-resistant anaemia.

NICE guideline Published June 2015

Nivolumab for previously treated advanced renal cell carcinoma (TA417)

Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma (RCC/kidney cancer) in adults

Technology appraisal guidance Published November 2016

Tivozanib for treating advanced renal cell carcinoma (TA512)

Evidence-based recommendations on tivozanib (Fotivda) for previously untreated advanced renal cell carcinoma (RCC/kidney cancer) in adults

Technology appraisal guidance Published March 2018

Neutropenic sepsis: prevention and management in people with cancer (CG151)

This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.

Clinical guideline Published September 2012

Laparoscopic partial nephrectomy (IPG151)

Evidence-based recommendations on laparoscopic partial nephrectomy (keyhole surgery to remove kidney tumours)

Interventional procedures guidance Published January 2006

Single-port laparoscopic nephrectomy (IPG414)

Evidence-based recommendations on single-port laparoscopic nephrectomy (‘keyhole’ surgery) to remove a kidney

Interventional procedures guidance Published November 2011

Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma (kidney cancer) in adults

Technology appraisal guidance Published January 2018

Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors

Technology appraisal guidance Published January 2009

Palliative care for adults: strong opioids for pain relief (CG140)

This guideline covers safe and effective prescribing of strong opioids for pain relief in adults with advanced and progressive disease. It aims to clarify the clinical pathway for prescribing and help to improve pain management and patient safety. Care during the last 2 to 3 days of life is covered by care of dying adults in the last days of life.

Clinical guideline Published May 2012 Last updated August 2016

Urogenital conditions

Everything NICE has said on urogenital conditions in an interactive flowchart

NICE Pathway Published June 2015 Last updated April 2019

Immunosuppressive therapy for kidney transplant in adults (TA481)

Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults

Technology appraisal guidance Published October 2017

Immunosuppressive therapy for kidney transplant in children and young people (TA482)

Evidence-based recommendations on immunosuppressive therapy for kidney transplant in children and young people

Technology appraisal guidance Published October 2017

Sepsis

Everything NICE has said on the recognition, diagnosis and early management of sepsis in an interactive flowchart

NICE Pathway Published July 2016 Last updated April 2019

Non-Hodgkin's lymphoma: diagnosis and management (NG52)

This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.

NICE guideline Published July 2016

Irreversible electroporation for treating liver metastases (IPG445)

Evidence-based recommendations on irreversible electroporation (IRE) for treating liver metastases (secondary cancers)

Interventional procedures guidance Published February 2013

Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

Technology appraisal guidance Published June 2018 Last updated July 2018

Intravenous fluid therapy in children and young people in hospital (NG29)

This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.

NICE guideline Published December 2015

Entrectinib for treating NTRK fusion-positive solid tumours ID1512

In development [GID-TA10414] Expected publication date: 05 February 2020

Technology appraisal guidance In development

Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

dialysis or die. One patient in 5 has aHUS affecting organs other than the kidneys, most commonly the brain or heart. 2.2 aHUS can occur...

Technology appraisal guidance

Sepsis: recognition, diagnosis and early management (NG51)

This guideline covers the recognition, diagnosis and early management of sepsis for all populations. The guideline committee identified that the key issues to be included were: recognition and early assessment, diagnostic and prognostic value of blood markers for sepsis, initial treatment, escalating care, identifying the source of infection, early monitoring, information and support for patients and carers, and training and education.

NICE guideline Published July 2016 Last updated September 2017

Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published December 2017 Last updated July 2018

Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)

Evidence-based recommendations on irreversible electroporation (IRE) for treating primary lung cancer and metastases in the lung

Interventional procedures guidance Published February 2013

Bladder cancer: diagnosis and management (NG2)

This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.

NICE guideline Published February 2015

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)

Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

Technology appraisal guidance Published April 2018

Irreversible electroporation for treating primary liver cancer (IPG444)

Evidence-based recommendations on irreversible electroporation (IRE) for treating primary liver cancer

Interventional procedures guidance Published February 2013

Laparoscopic cystectomy (IPG287)

Evidence-based recommendations on laparoscopic cystectomy (keyhole surgery to remove the bladder)

Interventional procedures guidance Published February 2009

Pancreatitis (NG104)

This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.

NICE guideline Published September 2018

Minimally invasive video‑assisted parathyroidectomy (IPG501)

Evidence-based recommendations on minimally invasive (keyhole) video-assisted parathyroidectomy to remove abnormal parathyroid glands

Interventional procedures guidance Published August 2014

Type 2 diabetes in adults: management (NG28)

This guideline covers the care and management of type 2 diabetes in adults (aged 18 and over). It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

NICE guideline Published December 2015 Last updated August 2019

Haematological cancers: improving outcomes (NG47)

This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.

NICE guideline Published May 2016